Literature DB >> 10720272

Transplantation of embryonic porcine mesencephalic tissue in patients with PD.

J M Schumacher1, S A Ellias, E P Palmer, H S Kott, J Dinsmore, P K Dempsey, A J Fischman, C Thomas, R G Feldman, S Kassissieh, R Raineri, C Manhart, D Penney, J S Fink, O Isacson.   

Abstract

OBJECTIVE: To assess the safety and the effect on standardized clinical rating measures of transplanted embryonic porcine ventral mesencephalic (VM) tissue in advanced PD.
METHODS: Twelve patients with idiopathic PD underwent unilateral implantation of embryonic porcine VM tissue; six received cyclosporine immunosuppression and six received tissue treated with a monoclonal antibody directed against major histocompatibility complex class I. Patients were followed for 12 months and assessed by clinical examination, MRI, and 18F-levodopa PET. Porcine endogenous retrovirus testing was conducted by PCR-based method on peripheral blood mononuclear cells.
RESULTS: Cell implantation occurred without serious adverse events in all patients. Cultures were negative for bacterial and unknown viral contamination. No porcine endogenous retrovirus DNA sequences were found. MRI demonstrated cannula tracts within the putamen and caudate, with minimal or no edema and no mass effect at the transplant sites. In the medication-off state, total Unified Parkinson's Disease Rating Scale scores improved 19% (p = 0.01). Three patients improved over 30%. There were two patients with improved gait. 18F-levodopa PET failed to show changes on the transplanted side.
CONCLUSIONS: Unilateral transplantation of porcine embryonic VM cells into PD patients was well tolerated with no evidence of transmission of porcine endogenous retrovirus. Changes in standardized clinical PD rating measures were variable, similar to the results of the first trials of unilateral human embryonic allografts that transplanted small amounts of tissue.

Entities:  

Mesh:

Year:  2000        PMID: 10720272     DOI: 10.1212/wnl.54.5.1042

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  41 in total

Review 1.  The design of clinical trials for cell transplantation into the central nervous system.

Authors:  Pierre Cesaro
Journal:  NeuroRx       Date:  2004-10

Review 2.  The demise of UKXIRA and the regulation of solid-organ xenotransplantation in the UK.

Authors:  Sheila McLean; Laura Williamson
Journal:  J Med Ethics       Date:  2007-07       Impact factor: 2.903

3.  Large animal models are critical for rationally advancing regenerative therapies.

Authors:  Dustin R Wakeman; Andrew M Crain; Evan Y Snyder
Journal:  Regen Med       Date:  2006-07       Impact factor: 3.806

4.  Intracranial delivery of stem cells.

Authors:  Keith W Muir; John Sinden; Erik Miljan; Laurence Dunn
Journal:  Transl Stroke Res       Date:  2011-07-26       Impact factor: 6.829

5.  Embryonic pig liver, pancreas, and lung as a source for transplantation: optimal organogenesis without teratoma depends on distinct time windows.

Authors:  Smadar Eventov-Friedman; Helena Katchman; Elias Shezen; Anna Aronovich; Dalit Tchorsh; Benjamin Dekel; Enrique Freud; Yair Reisner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

Review 6.  Cell therapy in Parkinson's disease.

Authors:  Olle Lindvall; Anders Björklund
Journal:  NeuroRx       Date:  2004-10

Review 7.  Immune problems in central nervous system cell therapy.

Authors:  Roger A Barker; Håkan Widner
Journal:  NeuroRx       Date:  2004-10

Review 8.  Cell-based therapies in Parkinson's disease.

Authors:  Paul Greene
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

9.  Mapping full-length porcine endogenous retroviruses in a large white pig.

Authors:  C Herring; G Quinn; R Bower; N Parsons; N A Logan; A Brawley; K Elsome; A Whittam; X M Fernandez-Suarez; D Cunningham; D Onions; G Langford; L Scobie
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 10.  Cell Therapy for Parkinson's Disease: New Hope from Reprogramming Technologies.

Authors:  Zhiguo Chen
Journal:  Aging Dis       Date:  2015-11-17       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.